|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date01 Oct 1950 |
100 Clinical Results associated with Toho Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Toho Pharmaceutical Co., Ltd.
15 Mar 1990·The Journal of ImmunologyQ2 · MEDICINE
Degradation of IgA proteins by Pseudomonas aeruginosa elastase.
Q2 · MEDICINE
Author: Morihara, K ; Mestecky, J F ; Heck, L W ; Kulhavy, R M ; Alarcon, P G ; Russell, M W
AbstractHuman colostral IgA and myeloma proteins of both IgA1 and IgA2 subclasses were susceptible to cleavage by Pseudomonas aeruginosa elastase. Detailed analysis of the cleavage products of IgA myeloma proteins revealed complete degradation of Fab with no evidence of intact Fab fragments as intermediate cleavage products. In contrast, both IgA1 and IgA2 proteins were resistant to cleavage by alkaline protease from P. aeruginosa. The susceptibility of human IgA proteins to elastase suggests a mechanism by which P. aeruginosa might evade the potentially protective function of IgA by producing this enzyme.
100 Deals associated with Toho Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Toho Pharmaceutical Co., Ltd.